Inflammation, immunological reaction and role of infection in pulmonary hypertension.

Inflammation underlies a wide variety of physiological and pathological processes. Acute inflammation is the initial response of the body to harmful stimuli. Chronic inflammation, by contrast, is a prolonged, dysregulated and maladaptive response that involves active inflammation, tissue destruction and attempts at tissue repair. Over the past few years, such persistent inflammation has been shown to be associated with pulmonary hypertension (PH). Substantial advances in basic and experimental science have illuminated the role of inflammation and the underlying cellular and molecular mechanisms that contribute to PH. This review summarizes the experimental and clinical evidence for inflammation in various types of PH. In addition, it assesses the current state of knowledge regarding the inducers/triggers of chronic inflammation and infection, as well as the inflammatory mediators and cells that are involved in PH. Infiltration of inflammatory cells, such as dendritic cells, macrophages, mast cells, T-lymphocytes and B-lymphocytes, in the vascular lesions and an elevation of serum/tissue concentrations of proinflammatory cytokines and chemokines and their contribution to pulmonary vascular remodelling are reported in detail. We review the data supporting the use of inflammatory markers as prognostic and predictive factors in PH. Finally, we consider how new insights into inflammation in PH may identify innovative therapeutic strategies.

[1]  Horst Olschewski,et al.  Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[2]  R. Mohiaddin,et al.  Simvastatin as a treatment for pulmonary hypertension trial. , 2010, American journal of respiratory and critical care medicine.

[3]  M. Rock,et al.  T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension. , 2010, Respiratory medicine.

[4]  G. Butrous,et al.  Pulmonary vascular remodeling correlates with lung eggs and cytokines in murine schistosomiasis. , 2010, American journal of respiratory and critical care medicine.

[5]  A. Rieger,et al.  HIV–HCV co‐infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension , 2009, Journal of viral hepatitis.

[6]  Weiyan Wang,et al.  Impairment of Monocyte-derived Dendritic Cells in Idiopathic Pulmonary Arterial Hypertension , 2009, Journal of Clinical Immunology.

[7]  M. Maitland,et al.  Inflammation, growth factors, and pulmonary vascular remodeling. , 2009, Journal of the American College of Cardiology.

[8]  K. Hatzistergos,et al.  Inhibition of the SDF-1/CXCR4 Axis Attenuates Neonatal Hypoxia-Induced Pulmonary Hypertension , 2009, Circulation research.

[9]  T. Nawrot,et al.  C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[10]  E. Mark,et al.  Interleukin-6 Overexpression Induces Pulmonary Hypertension , 2009, Circulation research.

[11]  S. P. Nana-Sinkam,et al.  Human herpesvirus-8 infection of primary pulmonary microvascular endothelial cells. , 2008, American journal of respiratory cell and molecular biology.

[12]  G. Butrous,et al.  Pulmonary Vascular Disease in the Developing World , 2008, Circulation.

[13]  M. Humbert.  Mediators involved in HIV-related pulmonary arterial hypertension , 2008, AIDS.

[14]  R. Medzhitov.  Origin and physiological roles of inflammation , 2008, Nature.

[15]  M. Gomberg-Maitland,et al.  Prostacyclin therapies for the treatment of pulmonary arterial hypertension , 2008, European Respiratory Journal.

[16]  J. Novotná,et al.  Prevention of Mast Cell Degranulation by Disodium Cromoglycate Attenuates the Development of Hypoxic Pulmonary Hypertension in Rats Exposed to Chronic Hypoxia , 2008, Respiration.

[17]  R. Speich,et al.  Peripheral blood B lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls: a cross sectional study , 2008, Respiratory research.

[18]  V. Kurup,et al.  Pulmonary arterial remodeling induced by a Th2 immune response , 2008, The Journal of experimental medicine.

[19]  Peter Libby,et al.  Inflammatory mechanisms: the molecular basis of inflammation and disease. , 2007, Nutrition reviews.

[20]  R. Speich,et al.  Increased Regulatory and Decreased CD8+ Cytotoxic T Cells in the Blood of Patients with Idiopathic Pulmonary Arterial Hypertension , 2007, Respiration.

[21]  M. Humbert,et al.  Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. , 2007, American journal of respiratory and critical care medicine.

[22]  S. Archer,et al.  The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted , 2007, Proceedings of the National Academy of Sciences.

[23]  N. Voelkel,et al.  Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. , 2007, American journal of respiratory and critical care medicine.

[24]  M. Humbert,et al.  Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension , 2007, European Respiratory Journal.

[25]  M. Humbert,et al.  Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension , 2007, European Respiratory Journal.

[26]  M. Humbert,et al.  Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension , 2006, European Respiratory Journal.

[27]  M. Humbert,et al.  Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. , 2006, Chest.

[28]  H. Ishibashi-Ueda,et al.  Increased plasma monocyte chemoattractant protein‐1 level in idiopathic pulmonary arterial hypertension , 2006, Respirology.

[29]  L. Rubin.  Pulmonary arterial hypertension. , 2006, Proceedings of the American Thoracic Society.

[30]  T. Schulz,et al.  Absence of Kaposi's sarcoma-associated herpesvirus in patients with pulmonary arterial hypertension. , 2005, American journal of respiratory and critical care medicine.

[31]  D. Badesch,et al.  Autoimmunity and pulmonary hypertension: a perspective , 2005, European Respiratory Journal.

[32]  J. Moorman,et al.  Hepatitis C Virus and the Lung , 2005 .

[33]  M. Humbert,et al.  Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension , 2005, Thorax.

[34]  V. Aiello,et al.  Decreased numbers of T-lymphocytes and predominance of recently recruited macrophages in the walls of peripheral pulmonary arteries from 26 patients with pulmonary hypertension secondary to congenital cardiac shunts. , 2004, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[35]  R. Budhiraja,et al.  Endothelial Dysfunction in Pulmonary Hypertension , 2004, Circulation.

[36]  K. Brown,et al.  Expression of human herpesvirus 8 in primary pulmonary hypertension. , 2003, The New England journal of medicine.

[37]  M. Humbert,et al.  Inflammation in pulmonary arterial hypertension , 2003, European Respiratory Journal.

[38]  K. Ley,et al.  Journal of Thrombosis and Haemostasis, 1: 1699±1709 REVIEW ARTICLE The role of in¯ammation in vascular injury and repair , 2022 .

[39]  M. Fujita,et al.  Pulmonary hypertension in TNF-alpha-overexpressing mice is associated with decreased VEGF gene expression. , 2002, Journal of applied physiology.

[40]  M. Humbert,et al.  CX3C Chemokine Fractalkine in Pulmonary Arterial Hypertension , 2002 .

[41]  M. Humbert,et al.  Chemokine RANTES in severe pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.

[42]  T. Minamino,et al.  Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  H. Ohira,et al.  Athymic Nude Rats Develop Severe Pulmonary Hypertension following Monocrotaline Administration , 2000, International Archives of Allergy and Immunology.

[44]  R. Kasukawa,et al.  Pulmonary Hypertension in Rats 1. , 1995 .

[45]  M. Humbert,et al.  Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. , 1995, American journal of respiratory and critical care medicine.

[46]  N. Voelkel,et al.  Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. , 1994, American journal of respiratory cell and molecular biology.

[47]  B. Groves,et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.

[48]  M. Yacoub,et al.  Lung mast cells in plexogenic pulmonary arteriopathy. , 1991, Journal of clinical pathology.

[49]  D. Moodie,et al.  Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. , 1991, Journal of the American College of Cardiology.

[50]  I. Obeyesekere,et al.  Pulmonary hypertension and filariasis. , 1974, British heart journal.